Emerging preclinical animal models for FSHD

Trends in Molecular Medicine

Volumn 21, Issue 5, 2015, Pages 295-306

  Lek, Angela ^a,b,c   Rahimov, Fedik ^a,b,c   Jones, Peter L ^c   Kunkel, Louis M ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

DUX4; Facioscapulohumeral dystrophy; Muscular dystrophy

Indexed keywords

DOXYCYCLINE; FRG1 PROTEIN; HOMEODOMAIN PROTEIN; PARVOVIRUS VECTOR; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DUX4; TRANSCRIPTION FACTOR PITX1; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; AUTOSOMAL DOMINANT INHERITANCE; CHROMOSOME; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; EPIGENETICS; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HETEROCHROMATIN; HUMAN; MEDICAL RESEARCH; MOUSE STRAIN; MUSCULAR DYSTROPHY; NONHUMAN; OPEN READING FRAME; PATHOPHYSIOLOGY; REVIEW; TRANSGENIC ORGANISM; TRANSLATIONAL RESEARCH; VIRAL GENE DELIVERY SYSTEM; XENOGRAFT; ZEBRA FISH; ANIMAL; ANIMAL MODEL; GENETICS; PATHOLOGY;

ANIMALIA;

ANIMALS; HOMEODOMAIN PROTEINS; HUMANS; MODELS, ANIMAL; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL;

EID: 84929049022     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.02.011     Document Type: Review

References (71)

1. Deenen J.C.W., et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology 2014, 83:1056-1059.
2. Landouzy L., Dejerine J. De la myopathie atrophique progressive. Rev. Med. Fr. 1885, 5:81-253.
3. Zatz M., et al. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am. J. Med. Genet. 1998, 161:155-161.
4. Brouwer O.F., et al. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology 1991, 41:1878-1881.
5. Fitzsimons R.B., et al. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain 1987, 110:631-648.
6. Lemmers R.J., et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat. Genet. 2012, 44:1370-1374.
7. Van der Maarel S.M., et al. Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol. Med. 2011, 17:252-258.
8. Himeda C.L., et al. Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease. Antioxid. Redox Signal. 2014, Published online December 4, 2014. http://dx.doi.org/10.1089/ars.2014.6090.
9. Wijmenga C., et al. Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 1990, 336:651-653.
10. Van Deutekom J.C.T., et al. Evidence for subtelomeric exchange of 3.3kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. Hum. Mol. Genet. 1996, 5:1997-2003.
11. Wijmenga C., et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat. Genet. 1992, 2:26-30.
12. Lemmers R.J., et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010, 329:1650-1653.
13. Lemmers R.J., et al. Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 2004, 75:1124-1130.
14. Ricci G., et al. Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy. Brain 2013, 136:3408-3417.
15. Scionti I., et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 2012, 90:628-635.
16. Sacconi S., et al. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am. J. Hum. Genet. 2013, 93:744-751.
17. Hewitt J.E., et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum. Mol. Genet. 1994, 3:1287-1295.
18. Winokur S.T., et al. The DNA rearrangement associated with facioscapulohumeral muscular dystrophy involves a heterochromatin-associated repetitive element: implications for a role of chromatin structure in the pathogenesis of the disease. Chromosome Res. 1994, 2:225-234.
19. De Greef J.C., et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum. Mutat. 2009, 30:1449-1459.
20. Van Overveld P.G.M., et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat. Genet. 2003, 35:315-317.
21. Lemmers, R.J. et al. (2014) Department of Human Genetics.
22. Gaillard M-C., et al. Differential DNA methylation of the D4Z4 repeat in patients with FSHD and asymptomatic carriers. Neurology 2014, 83:733-742.
23. Gabriels J., et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3kb element. Gene 1999, 236:25-32.
24. Dixit M., et al. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18157-18162.
25. Snider L., et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 2010, 6:e1001181.
26. Jones T.I., et al. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: Evidence for disease modifiers and a quantitative model of pathogenesis. Hum. Mol. Genet. 2012, 21:4419-4430.
27. Geng L.N., et al. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev. Cell 2012, 22:38-51.
28. Tassin A., et al. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?. J. Cell. Mol. Med. 2013, 17:76-89.
29. Tsumagari K., et al. Gene expression during normal and FSHD myogenesis. BMC Med. Genomics 2011, 4:67.
30. Winokur S.T., et al. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum. Mol. Genet. 2003, 12:2895-2907.
31. Bosnakovski D., et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 2008, 27:2766-2779.
32. Klooster R., et al. Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. Eur. J. Hum. Genet. 2009, 17:1615-1624.
33. Gabellini D., et al. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 2002, 110:339-348.
34. van Deutekom J.C.T. Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Hum. Mol. Genet. 1996, 5:581-590.
35. Rijkers T., et al. FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients. J. Med. Genet. 2004, 41:826-836.
36. van Geel M., et al. Identification of a novel β-tubulin subfamily with one member (TUBB4Q) located near the telomere of chromosome region 4q35. Cytogenet. Genome Res. 2000, 88:316-321.
37. Caruso N., et al. Deregulation of the protocadherin gene FAT1 alters muscle shapes: implications for the pathogenesis of facioscapulohumeral dystrophy. PLoS Genet. 2013, 9:e1003550.
38. Ansseau E., et al. DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation. PLoS ONE 2009, 4:e7482.
39. Cabianca D.S., et al. A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in fshd muscular dystrophy. Cell 2012, 149:819-831.
40. Snider L., et al. RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum. Mol. Genet. 2009, 18:2414-2430.
41. Block G.J., et al. Asymmetric bidirectional transcription from the FSHD-causing D4Z4 array modulates DUX4 production. PLoS ONE 2012, 7:e35532.
42. Reed P.W., et al. Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy. Exp. Neurol. 2007, 205:583-586.
43. Pandey S.N., et al. Conditional over-expression of PITX1 causes skeletal muscle dystrophy in mice. Biol. Open 2012, 1:629-639.
44. Dmitriev P., et al. Defective regulation of microRNA target genes in myoblasts from facioscapulohumeral dystrophy patients. J. Biol. Chem. 2013, 288:34989-35002.
45. Harafuji N., et al. miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors. Orphanet J. Rare Dis. 2013, 8:55.
46. Leidenroth A., Hewitt J.E. A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene. BMC Evol. Biol. 2010, 10:364.
47. Sharma V., et al. DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 Cells. PLoS ONE 2013, 8:e64691.
48. Young J.M., et al. DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis. PLoS Genet. 2013, 9:e1003947.
49. Ferri G., et al. Direct interplay between two candidate genes in FSHD muscular dystrophy. Hum. Mol. Genet. 2015, 24:1256-1266.
50. Celegato B., et al. Parallel protein and transcript profiles of FSHD patient muscles correlate to the D4Z4 arrangement and reveal a common impairment of slow to fast fibre differentiation and a general deregulation of MyoD-dependent genes. Proteomics 2006, 6:5303-5321.
51. Wuebbles, R.D. et al. (2010) Testing the effects of FSHD candidate gene expression in vertebrate muscle development. 3, 386-400.
52. Mitsuhashi H., et al. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy. Hum. Mol. Genet. 2013, 22:568-577.
53. Geng L.N., et al. Immunodetection of human double homeobox 4. Hybridoma 2011, 30:125-130.
54. Wallace L.M., et al. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann. Neurol. 2011, 69:540-552.
55. Krom Y.D., et al. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. PLoS Genet. 2013, 9:e1003415.
56. Dandapat A., et al. Dominant lethal pathologies in male mice engineered to contain an X-Linked DUX4 transgene. Cell Rep. 2014, 8:1484-1496.
57. Gabellini D., et al. Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 2006, 439:973-977.
58. Zhang Y., et al. Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Hum. Mol. Genet. 2014, 23. 3180-3108.
59. Broucqsault N., et al. Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to facio-scapulo-humeral dystrophy. Hum. Mol. Genet. 2013, 22:4206-4214.
60. Alexiadis V., et al. RNAPol-ChIP analysis of transcription from FSHD-linked tandem repeats and satellite DNA. Biochim. Biophys. Acta 2007, 1769:29-40.
61. Osborne R.J., et al. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 2006, 68:569-577.
62. Jiang G., et al. Testing the position-effect variegation hypothesis for facioscapulohumeral muscular dystrophy by analysis of histone modification and gene expression in subtelomeric 4q. Hum. Mol. Genet. 2003, 12:2909-2921.
63. Puppo F., et al. Identification of variants in the 4q35 gene FAT1 in patients with facioscapulohumeral dystrophy-like phenotype. Hum. Mutat. 2015, Published online January 23, 2015. http://dx.doi.org/10.1002/humu.22760.
64. Marcil A., et al. Pitx1 and Pitx2 are required for development of hindlimb buds. Development 2003, 130:45-55.
65. Gurnett C.A., et al. Asymmetric lower-limb malformations in individuals with homeobox PITX1 gene mutation. Am. J. Hum. Genet. 2008, 83:616-622.
66. Tonini M.M., et al. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul. Disord. 2004, 14:33-38.
67. Arashiro P., et al. Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6220-6225.
68. Rocha C.T., Hoffman E.P. Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies. Curr. Neurol. Neurosci. Rep. 2010, 10:267-276.
69. Pandya S., et al. Facioscapulohumeral dystrophy. Phys. Ther. 2008, 88:105-113.
70. Tawil R., et al. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet. Muscle 2014, 4:12.
71. Richards M., et al. Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?. Hum. Genet. 2012, 131:325-3340.